Skip to main content
Top
Published in: Breast Cancer Research 2/2011

Open Access 01-04-2011 | Research article

Targets of miR-200c mediate suppression of cell motility and anoikis resistance

Authors: Erin N Howe, Dawn R Cochrane, Jennifer K Richer

Published in: Breast Cancer Research | Issue 2/2011

Login to get access

Abstract

Introduction

miR-200c and other members of the miR-200 family promote epithelial identity by directly targeting ZEB1 and ZEB2, which repress E-cadherin and other genes involved in polarity. Loss of miR-200c is often observed in carcinoma cells that have undergone epithelial to mesenchymal transition (EMT). Restoration of miR-200c to such cells leads to a reduction in stem cell-like characteristics, reduced migration and invasion, and increased sensitivity to taxanes. Here we investigate the functional role of novel targets of miR-200c in the aggressive behavior of breast and endometrial cancer cells.

Methods

Putative target genes of miR-200c identified by microarray profiling were validated as direct targets using dual luciferase reporter assays. Following restoration of miR-200c to triple negative breast cancer and type 2 endometrial cancer cell lines that had undergone EMT, levels of endogenous target mRNA and respective protein products were measured. Migration and sensitivity to anoikis were determined using wound healing assays or cell-death ELISAs and viability assays respectively.

Results

We found that restoration of miR-200c suppresses anoikis resistance, a novel function for this influential miRNA. We identified novel targets of miR-200c, including genes encoding fibronectin 1 (FN1), moesin (MSN), neurotrophic tyrosine receptor kinase type 2 (NTRK2 or TrkB), leptin receptor (LEPR), and Rho GTPase activating protein 19 (ARHGAP19). These targets all encode proteins normally expressed in cells of mesenchymal or neuronal origin; however, in carcinoma cells that lack miR-200c they become aberrantly expressed and contribute to the EMT phenotype and aggressive behavior. We showed that these targets are inhibited upon restoration of miR-200c to aggressive breast and endometrial cancer cells. We demonstrated that inhibition of MSN and/or FN1 is sufficient to mediate the ability of miR-200c to suppress cell migration. Lastly, we showed that targeting of TrkB mediates the ability of miR-200c to restore anoikis sensitivity.

Conclusions

miR-200c maintains the epithelial phenotype not only by targeting ZEB1/2, which usually facilitates restoration of E-cadherin expression, but also by actively repressing a program of mesenchymal and neuronal genes involved in cell motility and anoikis resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119: 1420-1428. 10.1172/JCI39104.PubMedPubMedCentral Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119: 1420-1428. 10.1172/JCI39104.PubMedPubMedCentral
2.
go back to reference Moustakas A, Heldin C: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98: 1512-1520. 10.1111/j.1349-7006.2007.00550.x.PubMed Moustakas A, Heldin C: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98: 1512-1520. 10.1111/j.1349-7006.2007.00550.x.PubMed
3.
go back to reference Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454. 10.1038/nrc822.PubMed Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454. 10.1038/nrc822.PubMed
4.
go back to reference Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005, 17: 548-558. 10.1016/j.ceb.2005.08.001.PubMed Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005, 17: 548-558. 10.1016/j.ceb.2005.08.001.PubMed
5.
go back to reference Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14: 818-829. 10.1016/j.devcel.2008.05.009.PubMed Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14: 818-829. 10.1016/j.devcel.2008.05.009.PubMed
6.
go back to reference Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007, 7: 415-428. 10.1038/nrc2131.PubMed Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007, 7: 415-428. 10.1038/nrc2131.PubMed
7.
go back to reference Hurteau GJ, Carlson JA, Spivack SD, Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67: 7972-7976. 10.1158/0008-5472.CAN-07-1058.PubMed Hurteau GJ, Carlson JA, Spivack SD, Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67: 7972-7976. 10.1158/0008-5472.CAN-07-1058.PubMed
8.
go back to reference Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008, 10: 593-601. 10.1038/ncb1722.PubMed Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008, 10: 593-601. 10.1038/ncb1722.PubMed
9.
go back to reference Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9: 582-89. 10.1038/embor.2008.74.PubMedPubMedCentral Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9: 582-89. 10.1038/embor.2008.74.PubMedPubMedCentral
10.
go back to reference Park S, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22: 894-907. 10.1101/gad.1640608.PubMedPubMedCentral Park S, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22: 894-907. 10.1101/gad.1640608.PubMedPubMedCentral
11.
go back to reference Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010, 2010: 821717-PubMed Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010, 2010: 821717-PubMed
12.
go back to reference Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009, 8: 1055-1066.PubMedPubMedCentral Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009, 8: 1055-1066.PubMedPubMedCentral
13.
go back to reference Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008, 283: 14910-14914. 10.1074/jbc.C800074200.PubMedPubMedCentral Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008, 283: 14910-14914. 10.1074/jbc.C800074200.PubMedPubMedCentral
14.
go back to reference Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005, 24: 2375-2385. 10.1038/sj.onc.1208429.PubMed Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005, 24: 2375-2385. 10.1038/sj.onc.1208429.PubMed
15.
go back to reference Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A: The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007, 26: 6979-6988. 10.1038/sj.onc.1210508.PubMedPubMedCentral Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A: The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007, 26: 6979-6988. 10.1038/sj.onc.1210508.PubMedPubMedCentral
16.
go back to reference Hao J, Liu Y, Kruhlak M, Debell KE, Rellahan BL, Shaw S: Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J Cell Biol. 2009, 184: 451-462. 10.1083/jcb.200807047.PubMedPubMedCentral Hao J, Liu Y, Kruhlak M, Debell KE, Rellahan BL, Shaw S: Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J Cell Biol. 2009, 184: 451-462. 10.1083/jcb.200807047.PubMedPubMedCentral
21.
go back to reference Sossey-Alaoui K, Bialkowska K, Plow EF: The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 2009, 284: 33019-33029. 10.1074/jbc.M109.034553.PubMedPubMedCentral Sossey-Alaoui K, Bialkowska K, Plow EF: The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 2009, 284: 33019-33029. 10.1074/jbc.M109.034553.PubMedPubMedCentral
22.
go back to reference Fiévet B, Louvard D, Arpin M: ERM proteins in epithelial cell organization and functions. Biochim Biophy Acta. 2007, 1773: 653-660. 10.1016/j.bbamcr.2006.06.013. Fiévet B, Louvard D, Arpin M: ERM proteins in epithelial cell organization and functions. Biochim Biophy Acta. 2007, 1773: 653-660. 10.1016/j.bbamcr.2006.06.013.
23.
go back to reference Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, Xerri L, Viens P, Birnbaum D, Jacquemier J: Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007, 121: 1779-1785. 10.1002/ijc.22923.PubMed Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, Xerri L, Viens P, Birnbaum D, Jacquemier J: Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007, 121: 1779-1785. 10.1002/ijc.22923.PubMed
24.
go back to reference Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi S: Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res. 2004, 10: 572-580. 10.1158/1078-0432.CCR-1323-03.PubMed Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi S: Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res. 2004, 10: 572-580. 10.1158/1078-0432.CCR-1323-03.PubMed
25.
go back to reference Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, Samaniego R, Sánchez-Mateos P: Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009, 122: 3492-3501. 10.1242/jcs.053157.PubMed Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, Samaniego R, Sánchez-Mateos P: Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009, 122: 3492-3501. 10.1242/jcs.053157.PubMed
26.
go back to reference He M, Cheng Y, Li W, Liu Q, Liu J, Huang J, Fu X: Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer. 2010, 10: 170-10.1186/1471-2407-10-170.PubMedPubMedCentral He M, Cheng Y, Li W, Liu Q, Liu J, Huang J, Fu X: Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer. 2010, 10: 170-10.1186/1471-2407-10-170.PubMedPubMedCentral
27.
go back to reference Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, Zhao YZ, Wang Z, Chen F, Lee K, Fu SB: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 2009, 101: 327-334. 10.1038/sj.bjc.6605154.PubMedPubMedCentral Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, Zhao YZ, Wang Z, Chen F, Lee K, Fu SB: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 2009, 101: 327-334. 10.1038/sj.bjc.6605154.PubMedPubMedCentral
28.
go back to reference Ding J, Li D, Wang X, Wang C, Wu T: Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell. Hepatogastroenterology. 2008, 55: 2072-2076.PubMed Ding J, Li D, Wang X, Wang C, Wu T: Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell. Hepatogastroenterology. 2008, 55: 2072-2076.PubMed
29.
go back to reference Michael KE, Dumbauld DW, Burns KL, Hanks SK, García AJ: Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell. 2009, 20: 2508-2519. 10.1091/mbc.E08-01-0076.PubMedPubMedCentral Michael KE, Dumbauld DW, Burns KL, Hanks SK, García AJ: Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell. 2009, 20: 2508-2519. 10.1091/mbc.E08-01-0076.PubMedPubMedCentral
30.
go back to reference Tcherkezian J, Lamarche-Vane N: Current knowledge of the large RhoGAP family of proteins. Biol Cell. 2007, 99: 67-86. 10.1042/BC20060086.PubMed Tcherkezian J, Lamarche-Vane N: Current knowledge of the large RhoGAP family of proteins. Biol Cell. 2007, 99: 67-86. 10.1042/BC20060086.PubMed
31.
go back to reference Schulz LC, Widmaier EP: The effect of leptin on mouse trophoblast cell invasion. Biol Reprod. 2004, 71: 1963-1967. 10.1095/biolreprod.104.032722.PubMed Schulz LC, Widmaier EP: The effect of leptin on mouse trophoblast cell invasion. Biol Reprod. 2004, 71: 1963-1967. 10.1095/biolreprod.104.032722.PubMed
32.
go back to reference Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D: Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med. 1991, 196: 381-384.PubMed Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D: Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med. 1991, 196: 381-384.PubMed
33.
go back to reference Waxler SH, Brecher G, Beal SL: The effect of fat-enriched diet on the incidence of spontaneous mammary tumors in obese mice. Pro Soc Exp Biol Med. 1979, 162: 365-368. Waxler SH, Brecher G, Beal SL: The effect of fat-enriched diet on the incidence of spontaneous mammary tumors in obese mice. Pro Soc Exp Biol Med. 1979, 162: 365-368.
34.
go back to reference Wolff GL, Kodell RL, Cameron AM, Medina D: Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c × VY) F1 hybrid mice. J Toxicol Environ Health. 1982, 10: 131-142. 10.1080/15287398209530237.PubMed Wolff GL, Kodell RL, Cameron AM, Medina D: Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c × VY) F1 hybrid mice. J Toxicol Environ Health. 1982, 10: 131-142. 10.1080/15287398209530237.PubMed
35.
go back to reference Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004, 430: 1034-1039. 10.1038/nature02765.PubMed Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004, 430: 1034-1039. 10.1038/nature02765.PubMed
36.
go back to reference Geiger TR, Peeper DS: Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 2007, 67: 6221-6229. 10.1158/0008-5472.CAN-07-0121.PubMed Geiger TR, Peeper DS: Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 2007, 67: 6221-6229. 10.1158/0008-5472.CAN-07-0121.PubMed
37.
go back to reference Yu X, Liu L, Cai B, He Y, Wan X: Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci. 2008, 99: 543-552. 10.1111/j.1349-7006.2007.00722.x.PubMed Yu X, Liu L, Cai B, He Y, Wan X: Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci. 2008, 99: 543-552. 10.1111/j.1349-7006.2007.00722.x.PubMed
38.
go back to reference Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010, 29: 2047-2059. 10.1038/onc.2009.486.PubMedPubMedCentral Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010, 29: 2047-2059. 10.1038/onc.2009.486.PubMedPubMedCentral
39.
go back to reference Ruoslahti E: Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 1999, 76: 1-20.PubMed Ruoslahti E: Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 1999, 76: 1-20.PubMed
40.
go back to reference Johnstone CN, Castellví-Bel S, Chang LM, Bessa X, Nakagawa H, Harada H, Sung RK, Piqué JM, Castells A, Rustgi AK: ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene. 2004, 336: 59-71. 10.1016/j.gene.2004.01.025.PubMed Johnstone CN, Castellví-Bel S, Chang LM, Bessa X, Nakagawa H, Harada H, Sung RK, Piqué JM, Castells A, Rustgi AK: ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene. 2004, 336: 59-71. 10.1016/j.gene.2004.01.025.PubMed
41.
go back to reference Gentile A, D'Alessandro L, Lazzari L, Martinoglio B, Bertotti A, Mira A, Lanzetti L, Comoglio PM, Medico E: Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene. 2008, 27: 5590-5598. 10.1038/onc.2008.173.PubMed Gentile A, D'Alessandro L, Lazzari L, Martinoglio B, Bertotti A, Mira A, Lanzetti L, Comoglio PM, Medico E: Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene. 2008, 27: 5590-5598. 10.1038/onc.2008.173.PubMed
42.
go back to reference Seoh ML, Ng CH, Yong J, Lim L, Leung T: ArhGAP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett. 2003, 539: 131-137. 10.1016/S0014-5793(03)00213-8.PubMed Seoh ML, Ng CH, Yong J, Lim L, Leung T: ArhGAP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett. 2003, 539: 131-137. 10.1016/S0014-5793(03)00213-8.PubMed
43.
go back to reference Zhang Z, Wu C, Wang S, Huang W, Zhou Z, Ying K, Xie Y, Mao Y: Cloning and characterization of ARHGAP12, a novel human rhoGAP gene. Int J Biochem Cell Biol. 2002, 34: 325-331. 10.1016/S1357-2725(01)00134-0.PubMed Zhang Z, Wu C, Wang S, Huang W, Zhou Z, Ying K, Xie Y, Mao Y: Cloning and characterization of ARHGAP12, a novel human rhoGAP gene. Int J Biochem Cell Biol. 2002, 34: 325-331. 10.1016/S1357-2725(01)00134-0.PubMed
44.
go back to reference Thiele CJ, Li Z, McKee AE: On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009, 15: 5962-5967. 10.1158/1078-0432.CCR-08-0651.PubMedPubMedCentral Thiele CJ, Li Z, McKee AE: On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009, 15: 5962-5967. 10.1158/1078-0432.CCR-08-0651.PubMedPubMedCentral
45.
go back to reference Smit MA, Geiger TR, Song J, Gitelman I, Peeper DS: A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol. 2009, 29: 3722-3737. 10.1128/MCB.01164-08.PubMedPubMedCentral Smit MA, Geiger TR, Song J, Gitelman I, Peeper DS: A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol. 2009, 29: 3722-3737. 10.1128/MCB.01164-08.PubMedPubMedCentral
46.
go back to reference Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, Landi S, Zhou Y, Liu H: An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009, 30: 2064-2069. 10.1093/carcin/bgp283.PubMed Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, Landi S, Zhou Y, Liu H: An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009, 30: 2064-2069. 10.1093/carcin/bgp283.PubMed
47.
go back to reference Mayr C, Bartel DP: Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009, 138: 673-684. 10.1016/j.cell.2009.06.016.PubMedPubMedCentral Mayr C, Bartel DP: Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009, 138: 673-684. 10.1016/j.cell.2009.06.016.PubMedPubMedCentral
48.
go back to reference Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA: Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010, 70: 2789-2798. 10.1158/0008-5472.CAN-09-3541.PubMedPubMedCentral Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA: Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010, 70: 2789-2798. 10.1158/0008-5472.CAN-09-3541.PubMedPubMedCentral
49.
go back to reference Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB: A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Res. 2010, 70: 6509-6515. 10.1158/0008-5472.CAN-10-0689.PubMedPubMedCentral Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB: A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Res. 2010, 70: 6509-6515. 10.1158/0008-5472.CAN-10-0689.PubMedPubMedCentral
50.
go back to reference Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JAF, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, Lund AH, Perrakis A, Raz E, Agami R: RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell. 2007, 131: 1273-1286. 10.1016/j.cell.2007.11.034.PubMed Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JAF, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, Lund AH, Perrakis A, Raz E, Agami R: RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell. 2007, 131: 1273-1286. 10.1016/j.cell.2007.11.034.PubMed
51.
go back to reference Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RAR, Lao K, Clarke MF: Down-regulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009, 138: 592-603. 10.1016/j.cell.2009.07.011.PubMedPubMedCentral Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RAR, Lao K, Clarke MF: Down-regulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009, 138: 592-603. 10.1016/j.cell.2009.07.011.PubMedPubMedCentral
52.
go back to reference Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009, 11: 1487-1495. 10.1038/ncb1998.PubMed Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009, 11: 1487-1495. 10.1038/ncb1998.PubMed
53.
go back to reference Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K: Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010, 39: 761-772. 10.1016/j.molcel.2010.08.013.PubMedPubMedCentral Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K: Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010, 39: 761-772. 10.1016/j.molcel.2010.08.013.PubMedPubMedCentral
Metadata
Title
Targets of miR-200c mediate suppression of cell motility and anoikis resistance
Authors
Erin N Howe
Dawn R Cochrane
Jennifer K Richer
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2867

Other articles of this Issue 2/2011

Breast Cancer Research 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine